BioRegenx, Inc Financials
This page shows BioRegenx, Inc (BRGX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Tiny revenue and high gross margins still cannot cover overhead, leaving the company reliant on external funding.
Cash generation improved faster than sales from FY2024 to FY2025: revenue slipped to$1.9M , yet free cash flow turned positive at$30K . That improvement looks like a cost reset, because selling and administrative expense fell from$5.9M to$2.0M rather than from a larger revenue base.
Balance-sheet strain is more severe than the income statement suggests: FY2025 current liabilities of
Gross margin reached
Financial Health Signals
We are recalculating BioRegenx, Inc's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
BioRegenx, Inc scores -142.16, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($7.3M) relative to total liabilities ($4.9M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
BioRegenx, Inc passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 3 profitability signals pass, 1 of 3 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, BioRegenx, Inc generates $-0.03 in operating cash flow ($39K OCF vs -$1.5M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
BioRegenx, Inc earns $-4.2 in operating income for every $1 of interest expense (-$1.2M vs $300K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
BioRegenx, Inc generated $1.9M in revenue in fiscal year 2025. This represents a decrease of 20.8% from the prior year.
BioRegenx, Inc's EBITDA was -$1.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
BioRegenx, Inc reported -$1.5M in net income in fiscal year 2025.
BioRegenx, Inc earned $0.00 per diluted share (EPS) in fiscal year 2025. This represents an increase of 100.0% from the prior year.
Cash & Balance Sheet
BioRegenx, Inc generated $30K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 105.8% from the prior year.
BioRegenx, Inc held $69K in cash against $182K in long-term debt as of fiscal year 2025.
BioRegenx, Inc had 969M shares outstanding in fiscal year 2025. This represents an increase of 1.3% from the prior year.
Margins & Returns
BioRegenx, Inc's gross margin was 81.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 10.2 percentage points from the prior year.
BioRegenx, Inc's operating margin was -67.1% in fiscal year 2025, reflecting core business profitability.
BioRegenx, Inc's net profit margin was -83.2% in fiscal year 2025, showing the share of revenue converted to profit.
Capital Allocation
BioRegenx, Inc invested $32K in research and development in fiscal year 2025.
BioRegenx, Inc invested $9K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 95.2% from the prior year.
BRGX Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $426K+10.5% | $386K-24.0% | $508K+13.9% | $446K-13.4% | $515K+11.9% | $460K-22.7% | $596K-18.8% | $734K |
| Cost of Revenue | $78K+16.5% | $67K-17.8% | $81K-13.0% | $94K-14.3% | $109K-20.8% | $138K+20.4% | $114K-56.7% | $264K |
| Gross Profit | $348K+9.3% | $319K-25.2% | $426K+21.0% | $352K-13.2% | $406K+25.8% | $323K-33.0% | $482K+2.5% | $470K |
| R&D Expenses | N/A | $32K | $0 | $0 | $0+100.0% | -$33K | $0-100.0% | $8K |
| SG&A Expenses | $396K-24.8% | $527K+21.9% | $433K-5.3% | $457K-22.6% | $590K-27.0% | $809K+242.3% | $236K-83.1% | $1.4M |
| Operating Income | -$50K+94.7% | -$936K-10961.1% | -$8K+92.1% | -$107K+44.3% | -$193K | N/A | -$327K+68.5% | -$1.0M |
| Interest Expense | $77K-6.2% | $82K+13.9% | $72K+1.4% | $71K-4.2% | $74K-52.6% | $157K+132.1% | $68K+1.8% | $66K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$26K+97.4% | -$1.0M-1163.3% | -$81K+54.8% | -$178K+33.2% | -$267K | N/A | -$395K+64.3% | -$1.1M |
| EPS (Diluted) | $0.00 | N/A | $0.00 | $0.00 | $0.00 | N/A | $0.00 | $0.00 |
BRGX Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $337K-18.0% | $411K-64.8% | $1.2M+1.5% | $1.2M+138.4% | $483K-5.1% | $509K-97.1% | $17.4M-3.0% | $17.9M |
| Current Assets | $190K-24.3% | $251K-8.0% | $273K+9.4% | $250K-15.2% | $294K-4.4% | $308K-17.0% | $371K+13.8% | $326K |
| Cash & Equivalents | $46K-34.0% | $69K+47.8% | $47K+1.1% | $46K-44.4% | $84K+43.2% | $58K-16.7% | $70K+22.1% | $57K |
| Inventory | $93K-13.2% | $107K-2.2% | $109K-18.5% | $134K-4.4% | $140K+26.4% | $111K-30.0% | $159K+10.3% | $144K |
| Accounts Receivable | $18K-53.7% | $40K-36.6% | $63K+196.5% | $21K+89.3% | $11K-25.6% | $15K-22.9% | $19K+77.7% | $11K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | $7.1M0.0% | $7.1M |
| Total Liabilities | $4.9M-1.6% | $4.9M+2.8% | $4.8M+0.2% | $4.8M+18.9% | $4.0M+4.0% | $3.9M+2.3% | $3.8M+3.6% | $3.7M |
| Current Liabilities | $4.0M-1.9% | $4.1M+3.4% | $3.9M+0.2% | $3.9M+3.7% | $3.8M+4.2% | $3.6M+3.3% | $3.5M+2.9% | $3.4M |
| Long-Term Debt | N/A | $182K | N/A | N/A | N/A | $255K | N/A | N/A |
| Total Equity | -$4.5M+0.1% | -$4.5M-24.4% | -$3.6M+0.2% | -$3.7M-2.7% | -$3.6M-5.3% | -$3.4M-124.9% | $13.6M-4.6% | $14.2M |
| Retained Earnings | -$37.1M-0.1% | -$37.1M-2.8% | -$36.1M-0.2% | -$36.0M-0.5% | -$35.8M-0.8% | -$35.6M-107.2% | -$17.2M-2.4% | -$16.8M |
BRGX Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $27K-61.8% | $70K+197.3% | -$72K-2332.9% | $3K-91.5% | $38K+431.8% | -$11K+63.6% | -$31K+82.4% | -$177K |
| Capital Expenditures | N/A | $3K-49.0% | $6K | $0 | $0 | $0 | $0 | $0 |
| Free Cash Flow | N/A | $67K+185.8% | -$78K-2520.1% | $3K-91.5% | $38K+431.8% | -$11K+63.6% | -$31K+82.4% | -$177K |
| Investing Cash Flow | N/A | -$3K+49.0% | -$6K+88.0% | -$50K | $0-100.0% | $3K | $0 | $0 |
| Financing Cash Flow | -$50K-13.7% | -$44K-162.3% | $71K+321.0% | $17K+261.5% | -$10K-50.0% | -$7K-115.0% | $46K-61.3% | $120K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
BRGX Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 81.7%-0.9pp | 82.7%-1.3pp | 84.0%+4.9pp | 79.0%+0.2pp | 78.8%+8.7pp | 70.1%-10.7pp | 80.8%+16.8pp | 64.0% |
| Operating Margin | -11.7%+230.9pp | -242.6%-240.9pp | -1.7%+22.4pp | -24.1%+13.3pp | -37.4% | N/A | -54.9%+86.8pp | -141.7% |
| Net Margin | -6.2%+257.7pp | -263.9%-248.1pp | -15.9%+24.1pp | -40.0%+11.8pp | -51.8% | N/A | -66.3%+84.4pp | -150.7% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | -2.9%+4.9pp | -7.8% |
| Return on Assets | -7.8%+239.8pp | -247.7%-240.8pp | -6.9%+8.6pp | -15.5%+39.8pp | -55.3% | N/A | -2.3%+3.9pp | -6.2% |
| Current Ratio | 0.05-0.0 | 0.060.0 | 0.070.0 | 0.06-0.0 | 0.080.0 | 0.08-0.0 | 0.11+0.0 | 0.10 |
| Debt-to-Equity | N/A | N/A | N/A | N/A | N/A | N/A | 0.28+0.0 | 0.26 |
| FCF Margin | N/A | 17.3%+32.5pp | -15.3%-16.0pp | 0.7%-6.6pp | 7.3%+9.8pp | -2.5%+2.8pp | -5.2%+18.9pp | -24.2% |
Note: Shareholder equity is negative (-$4.5M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.06), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is BioRegenx, Inc's annual revenue?
BioRegenx, Inc (BRGX) reported $1.9M in total revenue for fiscal year 2025. This represents a -20.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is BioRegenx, Inc's revenue growing?
BioRegenx, Inc (BRGX) revenue declined by 20.8% year-over-year, from $2.3M to $1.9M in fiscal year 2025.
Is BioRegenx, Inc profitable?
No, BioRegenx, Inc (BRGX) reported a net income of -$1.5M in fiscal year 2025, with a net profit margin of -83.2%.
What is BioRegenx, Inc's EBITDA?
BioRegenx, Inc (BRGX) had EBITDA of -$1.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
How much debt does BioRegenx, Inc have?
As of fiscal year 2025, BioRegenx, Inc (BRGX) had $69K in cash and equivalents against $182K in long-term debt.
What is BioRegenx, Inc's gross margin?
BioRegenx, Inc (BRGX) had a gross margin of 81.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is BioRegenx, Inc's operating margin?
BioRegenx, Inc (BRGX) had an operating margin of -67.1% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is BioRegenx, Inc's net profit margin?
BioRegenx, Inc (BRGX) had a net profit margin of -83.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is BioRegenx, Inc's free cash flow?
BioRegenx, Inc (BRGX) generated $30K in free cash flow during fiscal year 2025. This represents a 105.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is BioRegenx, Inc's operating cash flow?
BioRegenx, Inc (BRGX) generated $39K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are BioRegenx, Inc's total assets?
BioRegenx, Inc (BRGX) had $411K in total assets as of fiscal year 2025, including both current and long-term assets.
What are BioRegenx, Inc's capital expenditures?
BioRegenx, Inc (BRGX) invested $9K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does BioRegenx, Inc spend on research and development?
BioRegenx, Inc (BRGX) invested $32K in research and development during fiscal year 2025.
What is BioRegenx, Inc's current ratio?
BioRegenx, Inc (BRGX) had a current ratio of 0.06 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is BioRegenx, Inc's return on assets (ROA)?
BioRegenx, Inc (BRGX) had a return on assets of -375.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Why is BioRegenx, Inc's debt-to-equity ratio negative or not reported?
BioRegenx, Inc (BRGX) has negative shareholder equity of -$4.5M as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is BioRegenx, Inc's Altman Z-Score?
BioRegenx, Inc (BRGX) has an Altman Z-Score of -142.16, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is BioRegenx, Inc's Piotroski F-Score?
BioRegenx, Inc (BRGX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are BioRegenx, Inc's earnings high quality?
BioRegenx, Inc (BRGX) has an earnings quality ratio of -0.03x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can BioRegenx, Inc cover its interest payments?
BioRegenx, Inc (BRGX) has an interest coverage ratio of -4.2x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.